The Role of Corticotropin-Releasing Factor Receptors in Mediating Stress-Induced Bladder Sensitivity in Female Mice

J. Christianson,A. Greenlief,X. Yang

DOI: https://doi.org/10.1016/j.jpain.2017.12.022

2018-01-01

Abstract:Patients with interstitial cystitis/painful bladder syndrome (IC/PBS) often report that their symptoms worsen during periods of heightened stress. Exposure to stress early in life can also increase susceptibility to developing IC/PBS, which has been linked to altered regulation of the hypothalamic-pituitary adrenal (HPA) axis. The HPA axis responds to a stressor by releasing corticotropin-releasing factor (CRF), driving downstream release of glucocorticoids. CRF also has peripheral actions on immune cells, bladder urothelium, and enteric neurons. Two CRF receptors have been described, CRF1 and CRF2, that act in opposition to one other to increase and decrease output from the HPA axis, respectively. Antagonism of either receptor has been shown to stabilize mast cells, thereby preventing stress-induced visceral hypersensitivity. Here, we are investigating the potential role of CRF receptors in preventing stress-induced bladder hypersensitivity in a mouse model of early life stress. Mouse pups underwent neonatal maternal separation (NMS) for 3 hours per day from postnatal day (P) 1 to 21 and were weaned on P22. At 10 weeks of age, the visceromotor response (VMR) to urinary bladder distension (UBD) was performed on female naïve and NMS mice. One week later, mice were treated with saline or a CRF1 antagonist (NBI 35965, 20 mg/kg, intraperitoneal) twenty minutes prior to a one hour exposure to water avoidance stress (WAS). Mice were retested for VMR during UBD at 24 hours and 7 days after WAS exposure. Saline-treated NMS mice had a significant increase in VMR at 1d post-WAS compared to baseline measurements and saline-treated naïve-mice. Treatment with CRF1 antagonist significantly decreased VMR in both naïve and NMS mice, at 1d-, but not 7d-post WAS. Our results suggest that antagonizing CRF1 may prevent stress-induced exacerbation of bladder hypersensitivity. Future studies will include testing with CRF2 antagonist and additional behavioral tests. Supported by NIH grant DK099611.